myLaurel® | $12,000,000 | (Jun 4, 2025)
Matterworks | Undisclosed Amount | (Jun 4, 2025)
Ciroos | $21,000,000 | (Jun 4, 2025)
Certified by Founder
Lodge
PAQ Therapeutics
start up
United States
- Burlington, MA
- 08/05/2025
- Series B
- $39,000,000
PAQ Therapeutics is a biotechnology company pioneering a new approach to restoring heath and curing disease through autophagy, the body’s most versatile mechanism for natural cellular degradation. With our ATTEC (autophagosome-tethering compound) technology, we are developing a novel class of small molecule degraders capable of binding a diverse array of substrates to the autophagy pathway including proteins, aggregates, lipids, organelles and pathogens. PAQ’s research advances in this important new class of degradation therapies have the potential to fundamentally transform drug discovery and development.
- Industry Biotechnology Research
- Website https://www.paqtx.com/
- LinkedIn https://www.linkedin.com/company/paq-therapeutics/
FISPAN | $30,000,000 | (Jun 4, 2025)
Volare Solutions | $29,578,562 | (Jun 4, 2025)
Skyral | $20,000,000 | (Jun 4, 2025)
Veris AI | $8,500,000 | (Jun 4, 2025)
Clara(US) | $3,100,000 | (Jun 4, 2025)
Akadeum Life Sciences, Inc. | $20,000,000 | (Jun 4, 2025)
ProteinQure | $11,000,000 | (Jun 4, 2025)
Heron Power | $38,000,000 | (Jun 3, 2025)
Trustifi | $25,000,000 | (Jun 3, 2025)